Genialis’ Post

Hello from Oxford! 🌍 Genialis' data scientists Eva Lavrenčič, Lea Vohar, and Jurij Nastran recently attended the MLx Health & Bio summer school at the Oxford Mathematical Institute. They delved into machine learning applications in drug discovery, genomics, public health, medical text mining, and immune system modeling. "Attending the summer school has enabled me to leverage advanced topics like representation learning and knowledge-aware ML. I'll use these skills to tackle even more challenging data science problems at Genialis," said Jurij. Next time, they promised to also try punting! 🛶 AI for Global Goals

Over a 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 biomarker studies exist in the literature. But in the real world, how many are FDA-approved to direct treatment decisions? Fewer than 𝟱𝟬. And for many new targeted therapies, the number drops to 𝟭. ⚠️ A big reason for this is that traditional approaches to biomarkers usually rely on a single analyte (like DNA) and yield a single data point (mutation status +/-). Leveraging multimodal datasets that include, for example, RNAseq data, offers a much better understanding of the underlying biology of the disease. 🔍 This new approach has led to biomarkers with pan-cancer potential and applicability to entire classes of drugs. Read more: https://lnkd.in/djcjbTvi

📢 Genialis is rapidly expanding its business and strategic partnerships in the US and globally. To drive this growth, we're #hiring a Business Development Associate. Read more and apply here: https://lnkd.in/dC3caMsR

“[Genialis’] approach begins with biology, and it is very different from other companies," said Debiopharm's Head of Translational Medicine Carolina Haefliger. 💡 "We thought [the approach] would be useful to solve the questions we have about biomarkers and DNA damage response agents. They may provide an answer that would normally take a lot of resources and time when you need to move a drug through the development path.” Genialis' efforts to increase the odds of clinical trial success and help promising new medicines reach patients with our novel approach to first-in-class biomarkers were recently presented in an article by Sifted. ➡️ Learn more about how Debiopharm Innovation Fund helps make this possible: https://lnkd.in/g62APAKh

Today 𝟱𝟴% of Genialis colleagues run regularly. 🏃♀️ But just 3 months ago, the number was closer to 𝟭𝟴%. How did that change so dramatically? Well, we've started a new weekly tradition. Every Friday morning, those interested take a break from work and hit the road with running coach Kristian. 💪 Stay tuned to hear how folks are progressing from 0 to 10k (with some even aiming for a half-marathon!) for a race in September.

We're joined in our mission to transform medicine through data and to develop tomorrow’s standard of care. Proud to be featured in Sifted as part of the Debiopharm Innovation Fund.

There are as many KRASi drug candidates as Wimbledon 🎾 tennis players right now. Sounds like a lot. But given the high failure rate of clinical trials, only a small handful out of ~100 will survive to compete for the cup. 📉 These odds do no favors for drug developers nor for patients. One way to change the game is to tap into the unrealized opportunities of predictive biomarkers. Read more about it in a recent article by GlobalData: https://lnkd.in/dEZG3NdD

Did you ever tag along to one of your parents' workplaces when you were little? 👧 Drawing on whiteboards, spinning on office chairs—the kids of Genialis get to do it all, too. 🙂 But once a month, they also spend some quality time with their peers at 𝗚𝗲𝗻𝗶𝗮𝗹𝗶𝘀 𝗞𝗶𝗱𝘀 𝗟𝗲𝗴𝗼 𝗪𝗼𝗿𝗸𝘀𝗵𝗼𝗽𝘀, building all kinds of robots. Genialis data scientist Lea Vohar leads these workshops, swapping her daily tasks of complex biological data mining for teaching these budding scientists programming and problem-solving through play. 🤖 Can't wait to continue the workshops in the fall!

Introducing Krista McKerracher, a veteran in pharma oncology development and the new Chairperson of the Genialis Board of Directors. Ms. McKerracher has dedicated her career to innovation, focusing on finding new ways to treat patients who need it most. 🙏 With nearly three decades of experience in commercial and R&D leadership at Johnson & Johnson and Novartis Oncology, she has delivered many industry firsts. 1️⃣ She launched several first-in-class drugs in the hematology/oncology space. 2️⃣ She led the team that brought the first CRISPR Cas9 ex-vivo gene editing product to the clinic (HbF edited stem cells for hemoglobinopathies). 3️⃣ And today, she joins another "first." Genialis' novel approach leverages multidimensional omics data and machine learning to develop first-in-class biomarkers that help deliver the right drug for the right patient at the right time. Read more about Ms. McKerracher and how her expertise will enhance Genialis' mission to improve patient outcomes on the link in the comments. Debiopharm, Taiwania Capital

Most biomarkers answer simple yes/no questions like: "𝘐𝘴 𝘢 𝘮𝘶𝘵𝘢𝘵𝘪𝘰𝘯 𝘱𝘳𝘦𝘴𝘦𝘯𝘵?". But with the emergence of next generation biomarkers that measure complex biological patterns, we get informative answers to questions like: “𝘏𝘰𝘸 𝘭𝘪𝘬𝘦𝘭𝘺 𝘸𝘪𝘭𝘭 𝘵𝘩𝘪𝘴 𝘱𝘢𝘵𝘪𝘦𝘯𝘵 𝘳𝘦𝘴𝘱𝘰𝘯𝘥 𝘵𝘰 𝘵𝘢𝘳𝘨𝘦𝘵𝘦𝘥 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵?”. ✅ Find out more about these revolutionary new biomarkers, using multidimensional omics data and machine learning, at the Festival of Genomics & Biodata (June 12th - 13th) in Boston! On Wednesday, Genialis CEO Rafael Rosengarten will present on Genialis™ krasID, a first-in-class biomarker to predict clinical benefit of KRASi. 🤝 Don't miss Rafael's talk in the Live Lounge at 12:10 PM, following the presentation by AstraZeneca and preceding the one by Merck & Co. See you in our hometown! #FOGBoston Front Line Genomics Bethan Lumb